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Abstract 
Nucleoside monophosphates and monophosphonates have been known for a long time to 
exert favorable pharmacological effects upon intracellular delivery. However, their 
development as drug molecules has been hindered by the inherent poor drug-like properties 
of the monophosphate and monophosphonate groups. These include inefficient cellular 
uptake and poor in vivo stability, with this latter drawback being most relevant to 
monophosphates than monophosphonates. To address these limitations, numerous 
monophosphate and monophosphonate prodrug strategies have been developed and 
applied in the discovery of nucleoside monophosphate and monophosphonate prodrugs that 
can treat viral infections and cancer. The approval of sofosbuvir, a nucleoside 
monophosphate prodrug, highlighted the success to be had by employing these prodrug 
technologies in the discovery of nucleotide therapeutics. In this Miniperspective, we discuss 
the different key monophosphate and monophosphonate nucleoside prodrugs that entered 
clinical development, some of which may in the future be approved to treat various human 
diseases.    
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1. Introduction 
The effectiveness of nucleoside analogues in treating cancer and various infections that are 
caused by the human immunodeficiency virus (HIV), hepatitis B and C viruses (HBV and 
HCV, respectively) was established a few decades ago.1-4 A significant number of 
nucleoside analogues are now used daily in the clinics to treat these diseases.3 These 
molecules exert their therapeutic effects after being converted in vivo into their mono-, di- 
and triphosphates (Figure 1A). Since nucleoside analogues are structurally different from 
natural nucleosides, their phosphorylation by nucleoside/nucleotide kinases to generate the 
active metabolites is often of limited efficiency.5-7 This, as a result, has limited the therapeutic 
efficacy of many of these therapeutic agents. To overcome this shortcoming, it was initially 
thought that delivering the phosphorylated metabolites of these nucleoside analogues would 
overcome the kinase-dependent phosphorylation steps and hence achieve better potency. 
However, the introduction of phosphate groups (mono-, di- or tri-) into these nucleoside 
analogues made them more polar resulting in decreased transport into cells (Figure 1B).  
 
Figure 1. (A) A general representation of the intracellular activation of nucleoside analogues 
by phosphorylation to yield their pharmacologically active metabolites. (B) Nucleoside 
monophosphates and monophosphonates are not efficiently transported into cells. (C) 
Masked nucleoside monophosphates and monophosphonates cross the cell membrane, 
undergo a de-masking step to release the monophosphate or monophosphonate derivatives, 
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which are subsequently further phosphorylated to the active 
triphosphate/phosphonodiphosphate species. 
 
Additionally, the poor in vivo stability of the P-O bonds of phosphate groups has hindered 
their use. To address this latter point, the conversion of the α-phosphate groups of mono-
phosphorylated nucleoside analogues into the more stable phosphonate groups, which have 
relatively longer half-lives, was adopted.8 This approach led to the successful development 
of numerous nucleoside analogue phosphonates such as cidofovir (1, Figure 2)9 and 
tenofovir (2, Figure 2)9. Still, the polar nature of the phosphonate group at physiological pH 
(< 7.4), similar to phosphate groups, limits their transport into cells.  
 
Figure 2. Chemical structures of key phosphonates and mono(phosphate/phosphonate) 
prodrugs approved for clinical use.  
 
As the first phosphorylation step, which converts nucleoside analogues into their 
monophosphate counterparts, is often regarded as the rate-limiting step in their 
bioactivation, a number of prodrug technologies that mask monophosphate and 
monophosphonate groups to increase their lipophilicity and thus improve their cellular uptake 
have been developed.10-12 These technologies have been used with success in the discovery 
of numerous nucleoside monophosphate and monophosphonate prodrugs that are currently 
used to treat viral infections in humans, e.g. HIV, HBV and HCV. 
The latest nucleoside monophosphate and monophosphonate prodrugs approved by the US 
Food and Drug Administration (FDA) are sofosbuvir (3, Figure 2)13 and tenofovir 
alafenamide (4, Figure 2)14-16. Sofosbuvir is now used to treat patients with HCV while 
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tenofovir alafenamide is used in combination with other antiretrovirals for the treatment of 
HIV-1 infections and is also being pursued as a possible treatment for HBV.17, 18 The 
success of these two prodrugs highlighted again the application of monophosphate and 
monophosphonate prodrug technologies as a powerful strategy in the discovery of 
nucleotide therapeutics. Herein, we will discuss the different monophosphate and 
monophosphonate prodrug strategies that have delivered clinical nucleotide candidates.     
 
2. Pronucleotide Clinical Candidates 
The key ten monophosphate and monophosphonate prodrugs that will be discussed in this 
Miniperspective employ a range of phosphate and phosphonate masking groups that are 
enzymatically cleaved off inside cells to release the monophosphate or monophosphonate 
species. Subsequent phosphorylation of these compounds yields the active di- or 
triphosphate derivatives, which in turn produce the desired therapeutic effects as illustrated 
in Figure 1C. Notably, these monophosphate and monophosphonate prodrug approaches 
differ in the type of the masking group(s) as well as their in vivo demasking mechanisms. 
2.1. Phosphoramidate (ProTide) prodrugs 
Considering the pipeline of nucleotide prodrugs undergoing clinical trials, it is clear that the 
majority of them employ the phosphoramidate (ProTide)19 technology that was invented by 
Prof. Chris McGuigan (Cardiff University, UK). In the ProTide approach, the negative 
charges of the phosphate or phosphonate group are masked by an aryl motif and an amino 
acid ester group (Figure 3). Upon cell entry, the masking groups are cleaved off in two 
enzymatic steps to release the nucleoside analogue monophosphate or monophosphonate. 
The first metabolic step is initiated by esterases that cleave the ester motif of the ProTide. 
Under physiological pH (< 7.4), the unmasked, negatively charged carboxyl group carries 
out a nucleophilic attack on the phosphate or phosphonate group. This results in the leaving 
of the aryl motif and the formation of a highly unstable five-membered ring. A nucleophilic 
attack from a water molecule opens up this heterocyclic ring leading to the generation of a 
phosphoramidate metabolite. A second enzyme, termed phosphoramidase-type enz
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(histidine triad nucleotide-binding protein 1, HINT-1),20 mediates the cleavage of the P-N 
bond of this metabolite leading to the release of the nucleoside analogue monophosphate or 
monophosphonate.21-23  
 
 
Figure 3. Postulated mechanism of ProTides in vivo breakdown to release the nucleoside 
analogue monophosphate or monophosphonate. 
 
This particular prodrug approach was adopted in the discovery of ProTides sofosbuvir and 
tenofovir alafenamide (Figure 2) with numerous other nucleoside ProTides entering clinical 
trials (Figure 4).  
 
Figure 4. Chemical structures of key nucleoside ProTides that entered clinical trials.  
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2.1.1. NUC-1031 and NUC-3373  
NUC-1031 (5, Figure 4)24 is an aryloxy triester phosphoramidate (ProTide) of the anticancer 
drug gemcitabine (Gemzar). The 5’-phosphate group is masked by a phenyl group and an 
L-alanine benzyl ester motif. This experimental medicine is currently being developed by 
NuCana Biomed Ltd. for the treatment of lung, ovary, breast, colon and pancreatic cancers. 
Strikingly, this ProTide was effective in treating cancers that are resistant to the parent 
therapeutic nucleoside gemcitabine.24 The ability of  ProTide 5 to overcome gemcitabine 
resistance25 was found to be due to three main reasons. First, compound 5 was able to 
overcome active cellular uptake mechanisms that limit the efficacy of gemcitabine as the 
prodrug is more lipophilic and enters cells through passive diffusion.24, 26 Second, the 
delivery of gemcitabine monophosphate using the ProTide approach overcame the 
dependency on the essential first activation step by deoxycytidine kinase, which is 
downregulated in some cancers.24, 26 Third, the delivery of gemcitabine monophosphate 
limited the deamination of the cytosine nucleobase, which generates the inactive uracil 
nucleos(t)ide metabolite, a process that reduces the efficacy of gemcitabine.24, 26 
Initial animal in vivo characterisation of 5 focused on pancreatic cancers that are either 
partially responsive or resistant to gemcitabine. These studies showed that 5 was superior to 
gemcitabine in two mouse xenograft models as it reduced the tumour size faster and the 
therapeutic effects lasted longer.26 Animals that lost < 2% of their weight, regained it after 
the treatment regimen was completed.26 In other studies, ProTide 5 dosed intravenously was 
better tolerated than gemcitabine as its maximum tolerated dose in Beagle dogs was 4-times 
equimolar higher than that of gemcitabine.27 Notably, the pharmacokinetics profile of 5 was 
also better than the parent nucleoside gemcitabine.27 For instance, the half-life of 5 was 7.9 
h compared to gemcitabine’s 1.5 h while the dosing of 5 generated 13-times higher 
intracellular concentrations of the active gemcitabine triphosphate metabolite than dosing 
with gemcitabine.27  
Results from phase I/II clinical trials showed that 5 was effective against a wide range of 
cancers that included pancreatic, biliary and ovarian.28 ProTide 5 achieved ca. 12-fold higher 
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levels of the active metabolite gemcitabine triphosphate than gemcitabine in patients similar 
to the levels seen in previous animal studies.27 This significant increase in the active 
metabolite was translated into better therapeutic efficacy. From 68 patients, five achieved 
tumour shrinkage of ≥ 30% while an additional thirty three patients had achieved stable 
disease.28 Generally, the prodrug was well-tolerated by patients with the most common 
adverse effects being anaemia (67%), fatigue (67%), transaminitis (64%) and 
thrombocytopaenia (53%).28 Compound 5 has reportedly entered phase III clinical trials in 
2015 as a potential treatment of pancreatic cancer. Additionally, a phase Ib trial examining 
the safety of 5 in combination with cisplatin in patients with locally advanced or metastatic 
biliary tract cancers is ongoing.  
Continuing with the theme of ‘ProTiding’ nucleosides that are known to exert anticancer 
activity, NuCana are currently developing a naphthyl L-alanine benzyl ester ProTide of 5-
fluoro-2’-deoxyuridine (FdU), the penultimate metabolite en route to the active metabolite of 
the chemotherapeutic agent 5-fluorouracil (5-FU). This prodrug, known as NUC-3373 (6, 
Figure 4),29 showed excellent preclinical properties.29 McGuigan and co-workers reported 
the discovery of 6 in 2011 and highlighted its advantageous properties as compared to the 
parent nucleoside FdU.30 Indeed, it was shown that compound 6 still exhibited significant 
cytotoxic properties in cells lacking thymidine kinase unlike the parent nucleoside FdU. This 
was thought to be due to the requirement of this nucleoside kinase to bioconvert FdU to its 
monophosphate analogue.29, 30 Interestingly, 6 was found to be resistant to inactivation by 
catabolic enzymes such as thymidine uridine phosphorylases, which inactivate FdU. Further 
studies showed the favourable chemical and serum stability of 6 as compared to the parent 
nucleoside FdU. Preclinical investigation showed that compound 6 generated an impressive 
363-times higher level of the active metabolite, FdU monophosphate, than the 
chemotherapeutic agent 5-FU.31 The significantly higher levels of the active metabolite were 
responsible for making ProTide 6 superior in efficacy compared to 5-FU in terms of tumour 
reduction in HT-29 colorectal xenografts.31 Coupling this favourable efficacy results with the 
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improved tolerability of 6 as compared to 5-FU,31 compound 6 has entered phase I clinical 
trials in Q4 2015. 
2.1.2. GS-5734 
GS-5734 (7, Figure 4)32 is a very interesting ProTide as it is currently the only C-nucleoside-
based ProTide undergoing clinical trials following the termination of the clinical development 
of the initial anti-HCV C-nucleotide ProTide, GS-662033 [structure not shown]. Although 
ProTide 7 is currently being developed by Gilead Sciences, Inc. for the treatment of Ebola, it 
exhibited broad spectrum antiviral activity against a selection of RNA viruses such as 
arenaviruses, coronaviruses and filoviruses. Structurally, compound 7 is a phenyl 2-
ethylbutyl L-alanine ester phosphoramidate of 1’-cyano-4-aza-7,9-dideaza adenosine. Unlike 
other ProTides in clinical development it is being pursued as a single isomer (Sp) akin to the 
two FDA-approved ProTides, sofosbuvir and tenofovir alafenamide (Figure 2). ProTide 7 
exhibited potent inhibition of the Ebola virus (EBOV) replication (EC50 = 0.06 to 0.14 μM) 
while the parent C-nucleoside was not as effective (EC50 = 0.77 to > 20 μM).32 This was 
attributed to the generation of higher levels of the C-nucleoside triphosphate active 
metabolite when 7 was used as compared to the parent C-nucleoside. 10mg/kg intravenous 
dosing of 7 in rhesus monkeys showed that the prodrug had a short half-life (t1/2 = 0.39 h), 
due to rapid clearance and fast metabolism to generate the alanine intermediate (compound 
7 with the unmasked alanine amino acid, but lacking the phenyl motif that masked the 
oxygen of the phosphate).32 Interestingly, the generation of the parent C-nucleoside was 
also observed suggesting a substantial dephosphorylation of the parent C-nucleoside 
monophosphate. In peripheral blood mononuclear cells (PBMCs), 7 was rapidly 
bioconverted to its active triphosphate derivative and achieved persistent high levels (t1/2 = 
14 h) that led to over 50% inhibition of EBOV replication in 24 h.32 Coupling these 
pharmacokinetic properties with tissue distribution studies, 7 was viewed as a suitable 
candidate for once-daily dosing.  Compound 7 was found to be effective in inhibiting EBOV 
replication in rhesus monkeys infected with Ebola virus as once-daily intravenous 
administration of 7 led to significant suppression of the Ebola virus replication and 100% 
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protection of infected animals against lethal disease. Indeed, different treatment regimens 
that ranged from 3 mg/kg to 10 mg/kg initiated at different time points following EBOV 
exposure (maximum 3 days) showed pronounced inhibition of EBOV replication and 
improved survival.32 Impressively, 10 mg/kg dosing starting from day 3 following virus 
exposure led to significant improvement in EBOV-related clinical signs and greater survival 
rates. Compound 7 dosed intravenously is currently undergoing phase I clinical trials for the 
treatment of Ebola virus disease. Additionally, given the broad spectrum of antiviral activity 
of this ProTide, as mentioned previously, it has the potential to be used in the treatment of 
other RNA viral infections that are currently difficult to treat.  
2.1.3. Stampidine and Thymectacin 
In 2009, we commented19 on the development of the two anti-HIV ProTide clinical 
candidates stampidine (8, Figure 4)34 and thymectacin (9, Figure 4)35, but not much 
information has been published on their progress since then.  
Stampidine was one of the first ProTides to enter clinical trials. It is a para-bromophenyl L-
alanine methyl ester ProTide of the FDA-approved anti-HIV reverse transcriptase inhibitor 
stavudine.34 As the first phosphorylation of the clinically used stavudine is rate-limiting in the 
formation of its active triphosphate species,36 the application of the ProTide technology to 
overcome this rate-limiting step was a logical one. Stampidine exhibited potent anti-HIV 
activity against wild-type HIV-1 strains as well as virus strains carrying mutations that give 
rise to resistance to nucleoside and non-nucleoside reverse transcriptase inhibitors.34, 37 As 
expected, this ProTide’s anti-HIV activity was retained in thymidine-kinase deficient cells 
confirming the ability of the ProTide technology to operate independently of this kinase. 
Unlike other ProTides in clinical development, which do not carry any substituents in the aryl 
motif of the ProTides, stampidine has a unique para-bromophenol motif. This introduction of 
the electron-withdrawing atom makes the metabolism of the ProTide take place quicker and 
hence the active triphosphate metabolite is generated faster. In vivo studies showed that 
stampidine was well tolerated. Indeed, no acute toxicity was detected in mice and rats dosed 
with up to 500 mg/kg of stampidine intraperitoneally or orally.38 Coupling this with favourable 
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tolerability, stampidine progressed to phase I clinical trials. Results from these studies 
involving oral dosing of stampidine did not show any dose-limiting toxicity at single dose 
levels of up to 25 mg/kg.39 Beyond its potential in treating HIV-resistant strains, stampidine 
was also suggested as a promising candidate in the pre-exposure prophylaxis against HIV in 
heterosexual women as well as serodiscordant couples.40 
Thymectacin35 is a phenyl L-alanine methyl ester ProTide of the therapeutic nucleoside 
brivudine (BVdU), which is used to treat herpes zoster (shingles).41, 42 Intriguingly, the 
ProTide of brivudine showed superior anticancer activity to its parent nucleoside 
(brivudine).43 This ProTide selectively targets tumour cells with a high expression of 
thymidylate synthase (TS) and shows at least 10-fold more cytotoxicity to 5-FU-resistant, TS 
over-expressing colorectal tumour cells than to healthy cells.35 As expected, thymectacin 
was metabolised in vivo to release the monophosphate derivative, which was expected to be 
further phosphorylated into the triphosphate and get incorporated into DNA causing 
cytotoxicity akin to other nucleoside therapeutics. However, this did not appear to be the 
case as cellular studies using radiolabelled thymectacin indicated that the released 
metabolite BVdU monophosphate was processed in a TS-dependent manner to generate 
reactive metabolites that resulted in the labelling of proteins.44 Although the identity of these 
labelled proteins remains elusive, the labelling of these proteins by BVdU monophosphate 
metabolites correlated well with the potency of thymectacin across the cells used in these 
studies. This pointed to a unique nucleotide-mediated labelling of proteins that causes 
cytotoxicity. Further studies into the mechanism of action of thymectacin suggested the 
involvement of the tumour suppressor p53 and the activation of the G2/M checkpoint 
eventually contributing to cell cycle arrest.45  
Phase I clinical trials of thymectacin dosed intravenously in patients with advanced colorectal 
cancer that failed 5-FU treatment was initiated. Initial results using doses ranging from 200 
mg/kg to 1250 mg/kg showed that thymectacin was well tolerated and a number of patients 
achieved a stable disease state.46 Among the serious side effects that were reported were 
respiratory distress, vomiting, hyperglycaemia and ascites. Despite the seemingly 
11 
 
encouraging results from this ProTide’s initial clinical results no further details on its 
development have been released.46 
Admittedly, despite the promising clinical data from stampidine and thymectacin, there has 
not recently been an update on their further development and thus their current state of 
clinical development is unclear. 
Beyond these ProTides that are reported to be in clinical development, the ProTide 
technology has delivered several other nucleoside monophosphate and monophosphonate 
prodrugs that entered clinical trials but eventually their development was suspended.47 This 
showcases the usefulness of this phosphate and phosphonate prodrug technology in the 
discovery of nucleotide therapeutics. 
 
2.2. HepDirect prodrugs 
Among the various phosphate and phosphonate prodrugs used in the discovery of 
nucleotide therapeutics, very few achieve tissue/organ targeting. Examples of these include 
the HepDirect48 approach, which is predominantly metabolised in the liver, via cytochrome 
P450 (CYP450) enzymes and thus achieves liver-targeted drug delivery (Figure 6).49 In this 
approach, the two negative charges of the phosphate are masked via the formation of a 
phenyldioxaphosphinane oxide. 
 
Fig. 6. Mechanism of CYP450-mediated metabolism of HepDirect prodrugs in the liver. 
 
These prodrugs undergo oxidation in the liver by CYP3A enzymes.49, 50 Intriguingly, this step 
was found to be dependent on the stereochemistry at the benzylic position.49 Indeed, only 
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prodrugs with cis-isomerism between the phosphate group and the nucleoside undergo 
cytochrome P450 3A (CYP3A) oxidation. Once oxidised, the prodrug moiety is quickly 
opened up to generate a mono-charged phosphate group. This intermediate subsequently 
undergoes β-elimination to generate a free unmasked phosphate group. The resulting aryl 
vinyl ketone released is rapidly detoxified by conjugation to glutathione, a process mediated 
by glutathione S-transferase. 
Due to the ability of this prodrug approach to be activated predominantly in the liver, it has 
been used extensively in the discovery of nucleotide therapeutics for the treatment of 
hepatitis infections. To date, it has been reported that two HepDirect nucleotide prodrugs 
have entered clinical development; pradefovir (10, Figure 7)51 and MB07133 (11, Figure 
7)52.  
 
Fig. 7. Chemical structures of two nucleotide HepDirect clinical candidates. 
 
2.2.1. Pradefovir 
Pradefovir is a HepDirect prodrug of the phosphonate adefovir, which is already used in the 
bis(pivaloyloxymethyl) (bisPOM) prodrug form (see section 2.4) in the treatment of HBV.51 
The use of the HepDirect prodrug approach in this case led to the targeting of adefovir to the 
liver, which limits the nephrotoxicity side effects associated with adefovir. Indeed, in rat liver, 
pradefovir showed 12-fold improvement in liver accumulation than adefovir and was 
accompanied by less accumulation in the kidney.51 Since the early pharmacokinetic profiles 
of pradefovir supported oral dosing, this drug candidate was subsequently pursued in the 
mesylate salt form in order to increase water solubility. The mesylate salt formulation 
achieved better oral bioavailability (42%) as compared to the parent drug (31%).51 Pradefovir 
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progressed into phase I and subsequently phase II clinical trials.53, 54 Indeed, in a 
randomised, open-label, parallel-group, multicentre study comparing pradefovir dosed at 5, 
10, 20 and 30 mg/day and adefovir dipivoxil dosed at 10 mg/day for 48-weeks, pradefovir 
was reported to be safe, well-tolerated and had significantly greater anti-HBV activity than 
adefovir dipivoxil.53 Notably, the only adverse effects reported were minor or mild with most 
of them being associated with the patient cohort placed on 30 mg/day dosing. Intriguingly, 
another open-label clinical study that aimed at comparing the long-term safety profiles of 
pradefovir and adefovir dipivoxil was terminated due to adverse findings from nonclinical 
carcinogenicity studies.55 Although this observation has complicated the further clinical 
development of pradefovir, it is reported to be still undergoing phase 2 clinical development 
in China for the treatment of HBV.56  
2.2.2. MB07133  
This HepDirect prodrug, which was granted Orphan Drug Designation by the FDA in 2007, 
was being developed as a possible treatment for hepatocellular carcinoma. It is a HepDirect 
prodrug of cytarabine, a nucleoside analogue used clinically to treat acute myelocytic 
leukaemia.57 Like many other therapeutic nucleosides, one of the limitations for using 
cytarabine is its poor in vivo phosphorylation (activation) to generate the active metabolite, 
cytarabine triphosphate. Attempts aimed at overcoming this bioconversion process to reach 
the therapeutic levels of the active triphosphate metabolite were often associated with 
myelosuppression due to generation of cytarabine triphosphate in health bone marrow 
cells.52  
As compared to cytarabine, compound 11 generated > 12-fold and > 19-fold higher levels of 
cytarabine triphosphate, the active metabolite, in the liver than in the bone marrow and the 
plasma, respectively.52 In animal studies, no toxic by-products from the monophosphate 
masking motifs were observed in hepatocytes or animals treated with 11. Data from a phase 
1/2 open label study to assess the safety, tolerability and pharmacokinetics of seven days 
continuous intravenous infusion of 11, at doses up to 2400 mg/m2/day, in subjects with 
unresectable hepatocellular carcinoma showed that it was well-tolerated, though a few 
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hepatic toxicities were noted.58 In another report it was noted that 11 was well-tolerated at 
doses up to 1800 mg/m2/day in patients suffering with unresectable hepatocellular 
carcinoma.59 Critically, in this study a few patients were reported to have experienced severe 
adverse effects, but these were suggested to be unrelated or unlikely related to compound 
11.59 
The clinical development of both nucleotide HepDirect clinical candidates, pradefovir and 11, 
was passed to Chiva Pharmaceuticals, Inc in 2011. Clinical data on the progress of these 
agents since has been scarce.  
2.3. Phosphate and phosphonate monoester prodrugs 
All of the phosphate and phosphonate prodrugs discussed already in this Miniperspective 
share a common feature of fully masking the phosphate or phosphonate group. In the 
alkoxyalkyl monoester prodrug approach,60 however, only one of the phosphate or 
phosphonate oxygens is masked while the second one is left free. The design of these ether 
lipid phospho-conjugates was inspired by the natural lysophosphatidylcholine. In these 
prodrugs, the choline moiety is replaced by the drug, and this conjugate benefits from active 
uptake mechanisms in the intestine leading to higher oral bioavailability. In order to reduce 
undesired in vivo conversions, further optimisation of the structures of these masking groups 
was undertaken and this led to the hexadecyloxypropyl (HDP) monoester prodrugs. These 
prodrugs are thought to be metabolised in vivo by phospholipases such as phospholipase C 
yielding the nucleoside monophosphate (Figure 8A).60, 61 This approach has proven to be 
successful in nucleotide therapeutics drug discovery and two nucleotide prodrugs are in 
clinical development; brincidofovir (12, Figure 8B)62 and CMX-157 (13, Figure 8B)63. 
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Fig. 8. Hexadecyloxypropyl (HDP) monoester prodrugs. A. Mechanism of nucleoside 
phosphate or phosphonate release in vivo from HDP prodrugs. B. Chemical structures of 
two nucleotide HDP clinical candidates. 
 
2.3.1. Brincidofovir  
Brincidofovir, also referred to as CMX-001, is an HDP monoester phosphate prodrug of the 
FDA-approved antiviral agent cidofovir.62 This prodrug has the advantage of being dosed 
orally unlike its parent drug cidofovir.62 Early in vitro studies showed that brincidofovir 
exhibited a broad spectrum of antiviral activity as it exerted potent activity against 
adenoviruses, smallpox, cytomegalovirus (CMV), papillomavirus, polyomavirus and 
orthopoxviruses.64 This antiviral activity was found to be due to cidofovir diphosphate, which 
inhibits viral DNA polymerases in double-stranded DNA viruses. Brincidofovir is more 
lipophilic than the parent drug cidofovir and also benefits from active transport in the small 
intestine. This resulted in 100-fold higher intracellular levels of the active cidofovir 
diphosphate from brincidofovir as compared to cidofovir.65 These differences in delivering 
the active species could explain the significant differences in (in vitro) antiviral activities 
between this prodrug and its parent drug, which could reach 100-fold difference.66 
Brincidofovir tissue distribution studies using radiolabelled brincidofovir showed it to be 
accumulated most in the small intestine followed by the liver, lung, kidney and spleen.67 
Interestingly, brincidofovir had lower accumulation in the kidney as compared to the parent 
drug cidofovir. This suggested that brincidofovir would not cause as much nephrotoxicity as 
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cidofovir, a common adverse effect associated with its use. The high accumulation of 
brincidofovir in the small intestine was linked to the gastrointestinal toxicities observed in 
animals when brincidofovir was dosed at high concentration.68 However, in healthy 
volunteers, there were no adverse effects observed when brincidofovir was dosed as a 
single dose at 2 mg/kg or multiple doses at 1 mg/kg while at higher doses increased rates of 
diarrhoea were noted.69 In a separate study, notable gastrointestinal adverse effects, 
particularly diarrhoea, were observed in a cohort of patients on doses of 200 mg of 
brincidofovir weekly or more with 200 mg twice weekly being dose-limiting.70 Phase I 
pharmacokinetic studies in which brincidofovir was dosed at a range of concentrations 
between 0.025 to 2 mg/kg as single and multiple doses indicated that cidofovir maximal 
plasma concentration was reached between 7 and 15 h.69 The half-life varied according to 
the doses used and was found to increase from 6.15 h with a 0.025 mg/kg dose to 32.7 h 
with a 1.5 mg/kg dose.69 Regarding the possible development of resistance against this 
experimental therapeutic agent, a recent study employing in vitro selection identified novel 
CMV UL54 DNA polymerase gene mutations that confer resistance to brincidofovir.71 
However, phase II clinical trials brincidofovir to placebo for prophylaxis against 
cytomegalovirus infection in hematopoietic cell transplant recipients indicated that there were 
no resistance-associated mutations detected in patients treated with brincidofovir.72 The 
study concluded that brincidofovir could be useful as a first-line agent in the prophylaxis of 
cytomegalovirus infection. Recent results from a double blind, placebo-controlled phase III 
trial that involved 452 subjects at high risk for CMV who received either brincidofovir or 
placebo twice-weekly for 24 weeks following hematopoietic cell transplantation (HCT) 
showed brincidofovir did not demonstrate statistically significant efficacy.73 Although the 
antiviral effect of brincidofovir was demonstrated at the end of the on-treatment period at 
week 14, by the primary end point of assessment (week 24) there were no significant 
differences in the clinically significant CMV infection in the cohorts treated with brincidofovir 
and those on the placebo.73 This unimpressive phase III data puts questions on the 
development of brincidofovir for the prophylaxis of CMV in HCT patients. Beyond CMV, 
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brincidofovir is also being pursued as a possible treatment of adenovirus and smallpox 
infections.74  
Interestingly, brincidofovir emerged as a promising agent in the fight against Ebola. This is 
quite intriguing as Ebola is not a DNA virus. Still, brincidofovir was found to inhibit Ebola 
virus in multiple human cell lines including HeLa and A549 cells.75 Unlike its mechanism of 
action of inhibiting DNA viruses, phosphorylation of brincidofovir did not seem to be required 
for activity. Instead, recent studies showed that the anti-Ebola activity required the lipid motif, 
i.e. the masking group.75 Indeed, the parent drug cidofovir alone did not show activity against 
Ebola while the lipid masking group alone was 29-fold less active than brincidofovir.75 
Encouraged by the promising activity of brincidofovir against Ebola, there were some efforts 
put into initiating human clinical trials investigating its efficacy against Ebola.76 However, the 
company developing brincidofovir, Chimerix, Inc., decided against this and focused its 
development on treating CMV and adenovirus infections.76     
2.3.2. CMX-157  
Compound 13 is an alkoxyalkyl monoester of the clinically used nucleoside phosphonate 
tenofovir.63 It was developed on the premise of being a lipophilic lysophosphatidylcholine 
(LPC) mimic to allow more efficient tenofovir delivery via the alternative, LPC uptake 
pathway. Additionally, the application of this alkoxyalkyl monoester prodrug approach was 
aimed at delivering a new therapeutic agent with better oral availability, efficacy and less 
nephrotoxic adverse effects than the parent drug tenofovir.63, 77 Compound 13 was > 300 fold 
more active than tenofovir and is active against the major subtypes of the HIV-1 virus.77 
Initial animal studies indicated that this agent was orally bioavailable and showed no 
significant toxicity following dosing of up to 100 mg/kg/day for 7 days.63 Encouraged by the 
preclinical data, 13 underwent phase I clinical trials where it demonstrated 267-fold higher 
activity than tenofovir in a dose-escalation, randomized, blinded trial where doses varied 
from a singular 25-400 mg dose of 13 or tenofovir.78 The results showed that single doses of 
13 were well tolerated by the patients. The antiviral activity was thought to be a result of the 
formation of tenofovir diphosphate, which was detectable in peripheral blood mononuclear 
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cells from patients following a single dose of 13.78 Interestingly, the tenofovir diphosphate 
levels were detectable for up to six days following a single dose of 400 mg of 13 suggesting 
the possibility of once a week dosing.79 Compound 13 is being developed by ContraVir 
Pharmaceuticals, Inc. and is currently undergoing phase II clinical trials as a potential 
treatment of HBV. 
2.4. BisPOM and bisPOC prodrugs 
BisPOM and bis(isopropyloxymethyl carbonate) (bisPOC) are two phosphate and 
phosphonate prodrugs that were used successfully in the discovery of nucleotide 
phosphonate prodrugs.10, 80, 81 Indeed, two bisPOM and bisPOC drugs, tenofovir 
disoproxil and adefovir dipivoxil, are currently used to treat HIV and HBV.20,21 The release of 
the nucleoside phosphate or phosphonate from these prodrugs is triggered by esterases 
(Figure 9). In the POC prodrug approach, the carbonate group is cleaved by esterases 
leading to the generation of the unstable carboxylate, which in turn undergoes two 
sequential degradation steps resulting in the formation of the nucleoside phosphate or 
phosphonate in addition to carbon dioxide and formaldehyde. In the POM approach, 
however, the process is rather simpler though still mediated by esterases and produces 
similar types of byproducts. The ester motif in POM is first cleaved by esterases and this 
leads to the formation of a highly unstable hydroxylmethyl alcoholate, which undergoes 
spontaneous rearrangement to generate formaldehyde and the nucleoside phosphate or 
phosphonate.   
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Fig. 9. Metabolism of (A) bisPOC and (B) bisPOM prodrugs. 
 
2.4.1. Besifovir 
Besifovir (14, Figure 10)82 is a bisPOM nucleotide phosphonate prodrug in clinical 
development as a potential treatment of HBV.83 It showed potent antiviral activity against 
wildtype HBV as well as lamivudine-, adefovir-, entecavir-, and telbivudine-HBV resistant 
strains.84 Besifovir is well absorbed and is rapidly degraded in the liver into the patent 
nucleotide, which is subsequently oxidized at the C6 position by oxidases such as xanthine 
oxidase.82, 85 The triphosphate derivative of the oxidized metabolite is the active species as it 
inhibits viral DNA replication.85  
 
Fig. 10. Chemical structure of Besifovir, an anti-HBV bisPOM prodrug clinical candidate. 
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Pharmacokinetics data showed besifovir has a long half-life supporting once-daily dosing.85 
Interestingly, the absorption of the prodrug was delayed by high fat diet.85 Initial data in mice 
showed that ca. 40% of the active metabolite was generated in the liver.85 In a placebo-
controlled randomized clinical trial, besifovir was dosed in patients with high viral load in 
escalating doses up to 240 mg/day for four weeks.85 The results showed significant viral load 
reduction in the cohort treated with besifovir as compared to the placebo group. In a phase II 
clinical trial looking into the safety and efficacy of 12-week treatment with besifovir in 
lamivudine-resistant patients, it was shown that viral HBV DNA was reduced in a dose-
dependent manner.86 Notably, for the first week of treatment, besifovir was combined with 
lamivudine.86 Although besifovir was generally well-tolerated, a number of patients had 
fluctuations of creatinine clearance.86 Importantly, 48-weeks treatment with besifovir led to 
significant HBV DNA reduction in HBeAg-positive and negative HBV patients. The results 
from a two year, head-to-head, multi-centre trial comparing besifovir at 90 mg and 150 mg 
with entecavir 0.5 mg in treatment-naïve chronic HBV patients, indicated that there were no 
significant differences in the treatment outcome parameters between patients receiving 
besifovir and entecavir.87 Although, during this two year trial, there were no identifiable 
resistance mutations and no significant nephrotoxicity, the patients taking besifovir suffered 
from depletion of carnitine, which is essential for the transportation of fatty acids from the 
cytosol to the mitochondria.88 This indicated that long-term use of besifovir needs to be 
accompanied with a carnitine supplement to overcome carnitine depletion. Additionally, 
significant reductions in phosphate blood levels were also observed in two patients taking 
besifovir.  
 
3. Conclusion 
The success of recently approved nucleotide prodrugs sofosbuvir and tenofovir alafenamide 
highlighted the usefulness of employing nucleoside monophosphate and monophosphonate 
prodrug technologies in the discovery of new therapeutics. Currently there is a selection of 
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nucleoside monophosphate and monophosphonate prodrugs in clinical development and an 
increasing number of these types of prodrugs in preclinical development. Although the vast 
majority of these prodrug (pre)clinical candidates are being developed to combat viral 
infections, there is an increasing interest in applying these prodrug technologies in the 
discovery of anticancer nucleotide therapeutics. Together, these point to the possibility of 
more nucleotide prodrugs being approved in the future to treat viral infections and cancers 
that are currently difficult to treat. Critically, the success of nucleoside monophosphate and 
monophosphonate prodrug technologies in delivering clinical candidates has reignited 
interest in the development of nucleos(t)ide therapeutics, which not a long time ago, were 
being viewed as an ‘outdated’ class of drugs. 
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